Showing results (231-240 of 253) with videos related to
Sort By:
Pageof 26
Drugs in R&D|August 24, 2017
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled TrialDavid J Webb, Blai Coll, Hiddo J L Heerspink, et al.Journal of Diabetes Science and Technology|September 6, 2023
The Effect of Insulin Degludec Versus Insulin Glargine U100 on Glucose Metrics Recorded During Continuous Glucose Monitoring in People With Type 1 Diabetes and Recurrent Nocturnal Severe HypoglycemiaJulie Maria Bøggild Brøsen, Rikke Mette Agesen, Amra Ciric Alibegovic, et al.Clinical Pharmacology and Therapeutics|July 27, 2022
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney DiseaseJ David Smeijer, Jeroen V Koomen, Donald E Kohan, et al.JACC. Heart Failure|June 30, 2022
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart FailureJ David Smeijer, Jeroen Koomen, Donald E Kohan, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 11, 2017
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKDDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.Lancet (London, England)|April 19, 2019
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trialHiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2013
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trialHiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, et al.Diabetes Technology & Therapeutics|April 25, 2022
Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe HypoglycemiaJulie Maria Bøggild Brøsen, Rikke Mette Agesen, Amra Ciric Alibegovic, et al.Diabetes, Obesity & Metabolism|February 7, 2023
Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemiaJulie Maria Bøggild Brøsen, Rikke Mette Agesen, Peter Lommer Kristensen, et al.Diabetologia|December 6, 2014
SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetesMarine Germain, Marcus G Pezzolesi, Niina Sandholm, et al.Pageof 26